Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated

Technology appraisal guidance
Reference number: TA387
Published: 27 April 2016
Last updated: 27 July 2016

Evidence

Supporting evidence

Review decision
Review decision – January 2019
Review decision paper (PDF 375 KB)

Published:

07 February 2019
Matrix of stakeholders (PDF 267 KB)

Published:

07 February 2019